Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (20669)	7/28/2006 11:53:34 AM
From: NeuroInvestment	Respond to of 52153

Cary: There has been no lack of effort to improve on tPA, either from the thrombolytic or the neuroprotectant angles. But stroke became an elephants graveyard for dozens of programs. Now the pendulum is swinging back to some companies (but generally not Big Pharma, which was so badly burned in the 90s) going after it again. Peter: Thanks for the info on Fibrogen. A different approach to raising EPO type factors (as Axaron is doing). I'll add it to my list of programs to watch. Harry NeuroInvestment